PROFILE 1005: PRELIMINARY PATIENT-REPORTED OUTCOMES (PROS) FROM AN ONGOING PHASE 2 STUDY OF CRIZOTINIB (PF-02341066) IN ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Blackhall, Fiona H. [1 ]
Petersen, Jennifer A. [2 ]
Wilner, Keith [3 ]
Hirsh, Vera [4 ]
Shaw, Alice T. [5 ]
Kim, Dong-Wan [6 ]
Solomon, Ben [7 ]
Janne, Pasi A. [8 ]
Reisman, Arlene L. [9 ]
Polli, Anna
Mundayat, Rajiv [10 ]
Bottomley, Andrew
机构：
[1] Christie Hosp NHS Trust, Manchester, Lancs, England
[2] Pfizer Oncol, Hlth Econ & Global Outcomes Res, New York, NY USA
[3] Pfizer Oncolgoy, Oncol Business Unit, New York, NY USA
[4] McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 2T5, Canada
[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[8] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Cambridge, MA 02138 USA
[9] Pfizer Oncol, Specialty BU, Stat, New York, NY USA
[10] Pfizer Oncol, Specialty Care Business Unit, Stat, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Crizotinib; PF-02341066; Non-small cell lung cancer; Symptons;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S413 / S414
页数：2
相关论文
共 50 条
  • [1] PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005
    Riely, Gregory J.
    Kim, Dong-Wan
    Crino, Lucio
    Janne, Pasi A.
    Blackhall, Fiona H.
    Camidge, David R.
    Hirsh, Vera
    Mok, Tony S. K.
    Solomon, Ben
    Soria, Jean-Charles
    Park, Keunchil
    Gadgeel, Shirish M.
    Martins, Renato G.
    Han, Ji-Youn
    De Pas, Tommaso
    Bottomley, Andrew
    Polli, Anna
    Petersen, Jennifer A.
    Tassell, Vanessa R.
    Shaw, Alice T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S411 - S412
  • [2] Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)
    Solomon, B.
    Bang, Y. J.
    Camidge, D. R.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [3] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [4] Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
    Camidge, D. R.
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Wilner, K. D.
    Costa, D. B.
    Shapiro, G.
    LoRusso, P.
    Stephenson, P.
    Tang, Y.
    Ruffner, K.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Crino, L.
    Kim, D.
    Riely, G. J.
    Janne, P. A.
    Blackhall, F. H.
    Camidge, D. R.
    Hirsh, V.
    Mok, T.
    Solomon, B. J.
    Park, K.
    Gadgeel, S. M.
    Martins, R.
    Han, J.
    De Pas, T. M.
    Bottomley, A.
    Polli, A.
    Petersen, J.
    Tassell, V. R.
    Shaw, A. T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors
    Li, C.
    Alvey, C.
    Bello, A.
    Wilner, K. D.
    Tan, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Kim, D. W.
    Blackhall, F.
    Soria, J. C.
    Solomon, B.
    Camidge, D. R.
    Riely, G. J.
    Bottomley, A.
    Tassell, V.
    Polli, A.
    Shaw, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S617 - S617
  • [8] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Camidge, D. R.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [9] VISUAL DISTURBANCES IN PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH CRIZOTINIB
    Besse, B.
    Salgia, R.
    Solomon, B.
    Shaw, A.
    Kim, D.
    Schachar, R.
    Wilner, K.
    Reisman, A.
    Bartlett, C. H.
    Iyer, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 416 - 416
  • [10] Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.
    Salgia, Ravi
    Solomon, Benjamin J.
    Shaw, Alice Tsang
    Camidge, D. Ross
    Evans, Tracey L.
    Kim, Dong-Wan
    Shi, Yuankai
    Han, Ji-Youn
    De Pas, Tommaso Martino
    Ou, Sai-Hong Ignatius
    Bartlett, Cynthia Huang
    Wilner, Keith D.
    Reisman, Arlene
    Iyer, Shrividya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345